BARKA Therapeutics ApS: Financial statements 2025
CVR: 44860627
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
BARKA Therapeutics ApS (CVR 44860627) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -961,543 and a net result of DKK -880,765. Equity in the 2025 report amounted to DKK -605,209.
- Revenue
- DKK 0
- Gross Profit
- DKK -961,543
- Profit/Loss
- DKK -880,765
- Equity
- DKK -605,209
- Total Assets
- DKK 837,664
- Employees
- 0
Official annual report
How creditworthy is BARKA Therapeutics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
BARKA Therapeutics ApS has published its interim report for the period May 29, 2024 – December 31, 2024.
About BARKA Therapeutics ApS
BARKA Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2024. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Hamed Mozaffari Brodersen. The board consists of Karin Absalonsen (chair), Claus Juan Møller-San Pedro, Hamed Mozaffari Brodersen and Ole Baadsgaard. The company is owned by Afyx Capital ApS and Hannibal Innovation ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -961,543 and a net result of DKK -880,765. Equity in the 2025 report amounted to DKK -605,209.